ロード中...
Prostate cancer cells express more androgen receptor (AR) following androgen deprivation, improving recognition by AR-specific T cells
Androgen deprivation is the primary therapy for recurrent prostate cancer, and agents targeting the androgen receptor (AR) pathway continue to be developed. Because androgen-deprivation therapy (ADT) has immmunostimulatory effects as well as direct antitumor effects, AR-targeted therapies have been...
保存先:
| 出版年: | Cancer Immunol Res |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5873299/ https://ncbi.nlm.nih.gov/pubmed/29051161 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-16-0390 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|